UK tech startup Temporall, founded by a former Google global director, has developed a world class AI and analytics-based platform to give key performance insights to leadership teams. Today the startup announced having raised more than €1 million seed funding from UK-based venture capital firm Luminous Ventures.
Temporall’s recent momentum has continued despite the current climate, with two new premium partnerships announced last month, along with two new senior tech hires. This expanding partner ecosystem is accelerating growth, with Temporall forecasting 900% revenue growth FY20 – FY22. Its current customers include major players like Google, Blue Prism, Rakuten, Dyson, Anthony Nolan and XL Media, demonstrating the startup has no signs of stopping.
Temporall’s founder and CEO Thomas Davies commented: “We’re tackling a global leadership problem that has actually been accentuated by the pandemic. All businesses have problems to solve and opportunities to pursue. But if the leadership team doesn’t have a clear picture of what’s happening within their own organisation, it makes it very difficult to get things done. This ‘partial insight’ causes strategies to fail and risk to be magnified. That’s why I started Temporall – to bring clarity to leaders. We help leadership teams understand where they are, what to do next and in what order.”
Izzy Fox, Co-Managing Partner of Luminous Ventures, Council Member at Innovate UK and Board advisor to Temporal, said: “Historically in the tech sector, we have seen innovation thrive, and forward-thinking businesses accelerate, following major disruption moments. The COVID-19 pandemic is the biggest such upheaval in almost a century. It has accentuated the need for organisations to be resilient, and to have real clarity on what’s happening across their own workforce. Temporall’s organisational intelligence platform – Workbench – answers this need. We believe it will change the way leadership teams make decisions, and it’s why we have built a seven figure seed+ fund structure with Temporall.”